Clinical efficacy,radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120 |
| |
| Authors: | Tsutomu Takeuchi Masayoshi Harigai Yoshiya Tanaka Hisashi Yamanaka Naoki Ishiguro Kazuhiko Yamamoto |
| |
| Institution: | 1. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan;2. tsutake@z5.keio.jp;4. Department of Epidemiology and Pharmacoepidemiology, Institute of Rheumatology, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan;5. First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan;6. Institute of Rheumatology, Tokyo Women?s Medical University, Shinjuku-ku, Tokyo, Japan;7. Department of Orthopedic Surgery, Nagoya University, Nagoya, Aichi, Japan;8. Department of Allergy and Rheumatology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan |
| |
| Abstract: | Objective: Evaluate the safety and efficacy of golimumab through week 120 in Japanese patients with active rheumatoid arthritis (RA) previously treated with DMARDs.Methods: Japanese patients with active RA despite prior DMARDs were randomized to placebo (Group 1, n?=?105), golimumab 50?mg (Group 2, n?=?101), or golimumab 100?mg (Group 3, n?=?102). At week 16, Group 1 patients crossed over to golimumab 50mg; after week 52, a one-time golimumab dose reduction from 100 to 50?mg was permitted. Assessments included ACR20/50/70 responses and good/moderate DAS28-ESR responses. Radiographic progression was assessed with the van der Heijde-modified Sharp (vdH-S) score. Safety and efficacy were assessed through week 120.Results: ACR20 response rates at week 52 in Group 1, Group 2, and Group 3 were 70.6%, 71.4%, and 81.9%, respectively, and maintained through week 104 (87.2%, 85.1%, 88.9%, respectively) and week 120 (86.1%, 87.0%, 89.5%, respectively). Similar trends were observed for ACR50, ACR 70, and DAS28-ESR. Median change in total vdH-S at weeks 52, 104, and 120 ranged from 0.0 to 1.5 across treatment groups. Through week 120, 93.8%/97.1% had an AE with golimumab 50?mg/100?mg, respectively, and 19.7%/11.8% had an SAE. Infections were the most common AE.Conclusion: Clinical response to golimumab 50?mg and 100?mg was maintained over 2 years in Japanese patients with active RA despite prior DMARDs. |
| |
| Keywords: | Anti-tumor necrosis factor golimumab Japanese rheumatoid arthritis |
|
|
